FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

<i>N</i> ashington,	D.C.	20549
---------------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	OMB APPROVAL									
	OMB Number:	3235-0287								
ı	Estimated average bu	rden								
	hours per response:	0.5								

					or	Section	n 30(f	n) of the	e Investr	ment (	Company Act	of 1940								
Name and Address of Reporting Person* <u>van Houte Hans</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Nurix Therapeutics, Inc. [ NRIX ]								Officer (give title Other				10% O	wner	
(Last) (First) (Middle) C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205							3. Date of Earliest Transaction (Month/Day/Year) 02/22/2021									X Officer (give title below) Other (specify below)  Chief Financial Officer				
(Street) SAN FRANCI	4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person  Form filed by More than One Reporting  Person										
		Tab	le I - I	Non-Deri	vative	e Sec	uriti	ies A	cquire	ed, D	isposed o	of, or B	enefici	ally	Owned	k				
Da		2. Transact Date (Month/Day			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		Transac	saction(s) :. 3 and 4)			(Instr. 4)			
Common Stock 02/22/2					021	21			<b>M</b> <sup>(1)</sup>		1,417	A	\$0.8	4	1,	1,417		D		
Common Stock 02/22/20				021	21		<b>M</b> <sup>(1)</sup>		3,913	A	\$1.	\$1.2		5,330		D				
Common Stock 02/22/202				021	21		S <sup>(1)</sup>		5,330	D	\$39.93	39.9323 <sup>(2)</sup>		0		D				
		Т	able								sposed of				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code ( 8)	action	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		cisable and	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. De Se (In	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Number of Shares	er						
Employee Stock Option (right to buy)	\$0.84	02/22/2021			M <sup>(1)</sup>			1,417	(3)	)	04/26/2026	Common Stock	1,41	7	\$0.00	68,333	3	D		
Employee Stock					(4)							Commo	2 2 2 2							

## **Explanation of Responses:**

\$1.2

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. Represents the weighted average sale price. The lowest price at which shares were sold was \$39.90 and the highest price at which shares were sold was \$40.03. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

(4)

03/01/2028

3,913

- 3. The option is fully vested.
- 4. The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

## Remarks:

Option

(right to buy)

> /s/ Christine Ring, as Attorney-02/23/2021 in-Fact for Hans van Houte

\*\* Signature of Reporting Person Date

3,913

\$0.00

29,420

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/22/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.